ADIPOQ and chronic kidney disease: According to the data collected to date, in CKD, the increase in adiponectin associates with decreased bone mineral density, development of anemia and LVH; however, beneficial associations, namely, in vascular calcification and lipid profile, have been also reported (Figure 3).